StockData
VASO Corp logo

VASO Corp (VASO) stock analysis

VASOOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 9/30
$0.29+0.00 (+0.06%)

Close on Oct 19, 2026Market cap $51.17MP/E 29.0Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth1Performance3Health5Dividend0

Mixed9 of 30 checks passed

VASO passes 9 of the 30 checks behind our score; 15 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
3/6
Financial health
5/6
Dividend
0/6

What stands out

  • No debt

    VASO has no borrowings on its latest balance sheet.

  • Earnings grew over 5 years

    Net income grew 34.4% a year on average over the last five fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Return on equity under 15%

    Return on equity was 9.0% over the last twelve months and averaged 34.4% over five years; we look for 15% on both.

  • Revenue growing under 10% a year

    Revenue grew 4.0% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -45.0% a year over the last three fiscal years.

  • Growing slower than the industry

    Revenue grew 3.4% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing under 10% a year

    Revenue grew 4.0% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -45.0% a year over the last three fiscal years.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 3.4% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 64.8% over the last twelve months, against 62.2% a year earlier.

Past performance3/6

  • Return on equity under 15%

    Return on equity was 9.0% over the last twelve months and averaged 34.4% over five years; we look for 15% on both.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity above the industry

    VASO's return on equity of 9.0% is above the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.

  • Earnings grew over 5 years

    Net income grew 34.4% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was 3.1% over the last twelve months, against a 5-year average of 6.2%.

  • Net margin above the industry

    VASO's net margin of 3.1% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Financial health5/6

  • No debt

    VASO has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 1.68 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    VASO has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for VASO. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 12.0
  • Surgical, Medical, and Dental Instruments and Supplies median 27.7

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2010 to 2025

Gross margin

61.4%+6.1 pts over 5 years

Operating margin

-3.2%−4.4 pts over 5 years

Net margin

1.8%+1.2 pts over 5 years

See a number that looks wrong?